Table 1.
Meta-analyses summarizing the association between VDR polymorphisms and AITD.
| Autor | N Included Studies | PMF | Population (Cases/Controls) | Main Results |
|---|---|---|---|---|
| Zhou H., Xu C., and Gu C., 2009 (data from 2000–2008) [86] | Nine on the relationship between VDR-PMF relationship with GD |
ApaI | 1820/1866 | Increased risk of GD in Asians (OR 1.31) No statistical association in Caucasians |
| BsmI | 1815/2066 | Increased risk of GD in Asians (OR 1.58) No statistical association in Caucasians |
||
| TaqI | 1348/1175 | No statistical association in Caucasians | ||
| FoxI | 1662/1840 | Increased risk of GD in Asians (OR 1.68) No statistical association in Caucasians |
||
| Feng M. et al. 2012 (data up to 08/2012) [87] | Eight on the relationship between VDR-PMF with AITD |
ApaI | 1009/1080 | No statistical association |
| BsmI | 1158/1049 | Risk decreased B allele vs. b (OR 0.801) | ||
| TaqI | 1211/1184 | Risk decreased t allele vs. T (OR 0.854) | ||
| FoxI | 739/924 | No statistical association | ||
| Gao X. and Yu Y., 2017 (data until 08/2017) [85] | Two on the relationship between VDR-PMF with AITD |
ApaI | 3544/3117 1 | Increased risk in Africans (OR 3.62) 1 No statistical association in general |
| BsmI | 3636/3373 1 | Reduced risk in Europeans (OR 0.79) 1 and Africans (OR 0.42) 1 Increased risk in Asians (OR 1.41) 1 |
||
| TaqI | 2950/2254 1 | Reduced risk of HT in the African population (OR 0.33) 1 | ||
| FoxI | 3174/2836 1 | Reduced risk of HT in the Asian population (OR 0.65) 1 | ||
| Veneti S. et al. 2019 (data up to 12/2018) [88] | Ten on the relationship between VDR-PMF relationship with GD |
ApaI | 2533/2474 | No statistical association |
| BsmI | 2536/2576 | No statistical association in general Risk decreased in Asians (OR 0.67), but increased in Caucasians (OR1.31) of subtype bb |
||
| TaqI | 2380/2235 | Increased risk of GD with TT (OR 1.42) | ||
| FoxI | 2587/2603 | No statistical association |
1 Dominant model. Abbreviations: AITD, autoimmune thyroid disease; GD, Graves’ disease; HT, Hashimoto thyroiditis; OR, odds ratio; PMF, polymorphism; VDR, vitamin D receptor.